Clinical Features of CML Patients Enrolled in the Study
| . | Total . | IFN Responders* . | IFN Nonresponders* . |
|---|---|---|---|
| No. of cases | 20 | 14 | 6 |
| Follow-up (mo) | |||
| Median | 7.5 | 7 | 8 |
| Range | 6-24 | 6-24 | 6-19 |
| WBC at Diagnosis (×103/μL) | |||
| Median | 119 | 112 | 126 |
| Range | 41-363 | 41-363 | 94-264 |
| Platelets at Diagnosis (No. of cases) | |||
| <400,000/μL | 6 | 4 | 2 |
| >400,000/μL | 14 | 10 | 4 |
| Splenomegaly at Diagnosis (No. of cases) | |||
| Absent | 5 | 3 | 2 |
| <5 cm | 8 | 5 | 3 |
| >5 cm | 7 | 6 | 1 |
| . | Total . | IFN Responders* . | IFN Nonresponders* . |
|---|---|---|---|
| No. of cases | 20 | 14 | 6 |
| Follow-up (mo) | |||
| Median | 7.5 | 7 | 8 |
| Range | 6-24 | 6-24 | 6-19 |
| WBC at Diagnosis (×103/μL) | |||
| Median | 119 | 112 | 126 |
| Range | 41-363 | 41-363 | 94-264 |
| Platelets at Diagnosis (No. of cases) | |||
| <400,000/μL | 6 | 4 | 2 |
| >400,000/μL | 14 | 10 | 4 |
| Splenomegaly at Diagnosis (No. of cases) | |||
| Absent | 5 | 3 | 2 |
| <5 cm | 8 | 5 | 3 |
| >5 cm | 7 | 6 | 1 |
See text for the operational definition of hematologic response to IFN-α treatment.